Growth hormone treatment in children in Israel: A large‐scale retrospective database study
Acta Paediatrica · 2025
DOI: 10.1111/apa.17535 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Paediatrica, 2025. Verfasst von Yael Reichenberg und 5 weiteren Autor:innen. Beteiligte Einrichtung: Dan-Petach Tikva District, Clalit Health Services, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Human Growth Hormone, Growth Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Novo Nordisk.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Aim
To evaluate the indications, population characteristics and latency between short stature diagnosis to treatment with recombinant growth hormone (GH) therapy in a large cohort of children in Israel.
Methods
We performed a retrospective medical chart review of all children treated with GH for conditions associated with short stature in three central districts in Israel from 1 January 2010 to 31 December 2021. Data extracted from the medical files included demographics, time to diagnosis, treatment indications and GH therapy duration.
Results
The study group comprised 5148 children aged 1 day to 17 years. A total of 64.1% were diagnosed with idiopathic short stature (ISS), 31.1% with GH deficiency (GHD) and 2.5% with small‐for‐gestational age (SGA). Males were treated more than females (58.9% vs. 41.1%). The mean age at first documentation of short stature was 6.9 ± 3.5 years. GH therapy was initiated at a mean age of 9.8 ± 3.3 years. A total of 51.2% were of high socio‐economic status (SES); 78.2% were non‐ultraorthodox Jews, 13%, ultraorthodox Jews, and 8.8% were Arabs.
Conclusion
Meticulous growth follow‐up from early childhood for all children, specifically females, those of low SES, and minorities is important to provide appropriate referral, treatment and final adult height outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dan-Petach Tikva District, Clalit Health Services, Tel Aviv, Israel.
- Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.
- The Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.
- Microbiology Unit, Ariel University, Ariel, Israel.
- Pediatric Ambulatory Community Clinic, Petach Tikva, Israel.
ORCID-Profile: Vered Shkalim Zemer
Förderung
- Novo Nordisk
Zitieren
APA
Reichenberg, Y., Bello, R., Oberman, B., Cohen, M., Cohen, A. H., & Shkalim Zemer, V. (2025). Growth hormone treatment in children in Israel: A large‐scale retrospective database study. Acta Paediatrica. https://doi.org/10.1111/apa.17535
Vancouver
Reichenberg Y, Bello R, Oberman B, Cohen M, Cohen AH, Shkalim Zemer V. Growth hormone treatment in children in Israel: A large‐scale retrospective database study. Acta Paediatrica. 2025. doi:10.1111/apa.17535
BibTeX
@article{Reichenberg2025,
author = {Reichenberg, Yael and Bello, Rachel and Oberman, Bernice and Cohen, Moryia and Cohen, Avner Herman and Shkalim Zemer, Vered},
title = {Growth hormone treatment in children in Israel: A large‐scale retrospective database study},
journal = {Acta Paediatrica},
year = {2025},
doi = {10.1111/apa.17535}
}
EUVIMED